DengiAll Could Become India's First Indigenous Dengue Shot
What Happened
DengiAll, India's first indigenous dengue vaccine developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR), could be available by 2027 if ongoing Phase 3 trials are successful. The vaccine is being tested across 20 centres with over 13,000 volunteers and is designed as a single-dose tetravalent vaccine that targets all four dengue virus strains.
Key Takeaways
If approved, DengiAll could become a major tool in India's fight against dengue by simplifying vaccination through a single-dose schedule and offering protection against all four dengue serotypes. However, its rollout will depend on the final clinical trial results and regulatory approvals.